hVIVO revenues dip but acquisitions bolster outlook amid industry slowdown

hVIVO PLC reported H1 2025 revenues of £24.2 million, a decline from £35.6 million year-over-year, and a reduced EBITDA margin of 12% from 24.5%, primarily attributed to delayed contracts and a subdued biotech funding environment. Despite the revenue dip, the clinical research group is trading in line with full-year expectations, with its recent acquisitions (CRS, Cryostore) bolstering the outlook. Management highlighted a robust £40 million orderbook and a growing sales pipeline, including potentially record-sized human challenge trials, expressing confidence in long-term growth and positioning for a strong 2026.

Analysis

hVIVO PLC's first-half 2025 performance reflects significant external pressure, with revenues declining to £24.2 million from £35.6 million year-over-year and EBITDA margins compressing sharply to 12% from 24.5%. These figures are attributed to delayed contracts and a subdued funding environment for its US biotech clients. Despite this contraction, the results align with full-year market expectations, suggesting the market had anticipated these headwinds. Positively, the company maintains a strong financial position, ending the period with £23.3 million in cash and no debt. Furthermore, a secured order book of £40 million provides a degree of revenue visibility. Management's guidance is optimistic, highlighting that its recent acquisition strategy is delivering results and pointing to a growing sales pipeline that includes several large human challenge trials described as potentially being among the largest in its history. This forward-looking commentary, combined with confidence in a 2026 growth trajectory, frames the current challenges as transient.

Key Decisions for Investors

• Investors should closely monitor company announcements for the conversion of the large contracts in the sales pipeline, as these are the primary catalyst for validating management's optimistic 2026 growth outlook.
• The company's strong, debt-free balance sheet with £23.3 million in cash should be considered a key mitigating factor against the sharp drop in revenue and profitability, providing a cushion to withstand the current sector-specific slowdown.
• Given the disconnect between poor current results and a positive long-term outlook, investment decisions should be based on a longer time horizon, focusing on H2 2025 execution and contract wins as critical indicators of a future recovery.